Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis

Jia, Xiaobo; Liu, Jiao; Gao, Yingtang; Huang, Yong; Zhi, Du

doi:10.1016/j.arcmed.2014.11.002

Cited by 71 publications

(60 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that GPC3 messenger RNA levels are increased in HCC [335, 336]. Whereas the role of GPC3 in immunohistochemical staining was established [337], the reported diagnostic performance of serum GPC3 was inconsistent, mainly due to heterogeneous and unestablished assay system [338]. …”

Section: Diagnosis and Surveillancementioning

confidence: 99%

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

et al. 2017

View full text Add to dashboard Cite

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems. Since the “Toward Revision of the Asian Pacific Association for the Study of the Liver (APASL) HCC Guidelines” meeting held at the 25th annual conference of the APASL in Tokyo, the newest guidelines for the treatment of HCC published by the APASL has been discussed. This latest guidelines recommend evidence-based management of HCC and are considered suitable for universal use in the Asia–Pacific region, which has a diversity of medical environments.

show abstract

Section: Diagnosis and Surveillancementioning

confidence: 99%

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

et al. 2017

View full text Add to dashboard Cite

show abstract

“…These biomarkers are being developed not only for use of HCC diagnosis, but also in prediction of patient and treatment outcomes and individualization of therapy [4–6]. Some of them are more promising, such as glypican-3(GPC3) [7], osteopontin(OPN) [8], Des-γ-carboxyprothrombin(DCP) [9], Golgi protein-73(GP73) [10] and microRNAs (miR-122 and miR-21, et al) [11, 12]. …”

Section: Introductionmentioning

confidence: 99%

Metallothionein 1M suppresses tumorigenesis in hepatocellular carcinoma

Pan

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Members of the metallothionein (MT) family are involved in metal detoxifcation and in the protection of cells against certain electrophilic carcinogens. In present study, it was found that MT1M was downregulated in more than 77.1% (91/118) of hepatocellular carcinoma (HCC) tissues compared with adjacent non-tumor tissues. Furthermore, overexpression of MT1M inhibited cell viability, colony formation, cell migration and invasion in HCC cell lines and tumor cell growth in xenograft nude mice, and activated cell apoptosis in HCC cell lines. In addition, immunohistochemistry analysis showed MT1M was negative or weak staining in tumor tissues but moderate or strong staining in adjacent non-tumor tissues. The sensitivity and specificity of MT1M for HCC diagnosis were 76.27% and 89.83%, respectively. In conclusion, MT1M was identified as a potential tumor marker for HCC and may serve as a useful therapeutic agent for HCC gene therapy.

show abstract

“…Unfortunately, the diagnostic performance of serum Glypican 3 (GPC3) which had a diagnostic value comparable to AFP in HCC diagnosis is still unsatisfactory for early-stage HCC [48]. However, both serum GPC-3 and GPC-3mRNA are promising diagnostic markers for early detection of HCC in Egyptian patients [35,49].…”

Section: Discussionmentioning

confidence: 99%

Identification of Cyclase-Associated Protein-2 as a Novel Biomarker for Early- Stage Hepatocellular Carcinoma

Mohammed¹,

Omar²,

Mohammed³

et al. 2017

J Clin Gastroenterol Hepatol

View full text Add to dashboard Cite

show abstract

Diagnosis Accuracy of Serum Glypican-3 in Patients with Hepatocellular Carcinoma: A Systematic Review with Meta-analysis

Cited by 71 publications

References 36 publications

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Metallothionein 1M suppresses tumorigenesis in hepatocellular carcinoma

Identification of Cyclase-Associated Protein-2 as a Novel Biomarker for Early- Stage Hepatocellular Carcinoma

Contact Info

Product

Resources

About